Enliven Therapeutics, Inc.
NASDAQ:ELVN · NASDAQ Global Select
-$0.12 today
Vol 2.16M · Avg 1.35M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ELVN · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$98.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.64, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $263.0K | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$263.0K | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $85.9M +6.3% | $80.8M +25.1% | $64.6M +108.2% | $31.0M +51.5% | $20.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $33.8M +42.2% | $23.8M +25.4% | $19.0M +144.0% | $7.8M +81.2% | $4.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $119.4M +14.2% | $104.6M +25.2% | $83.5M +115.3% | $38.8M +56.7% | $24.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $263.0K -17.0% | $317.0K +6.7% | $297.0K +38.1% | $215.0K +87.0% | $115.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$103.4M -16.9% | -$88.5M -24.1% | -$71.3M -90.4% | -$37.4M -52.1% | -$24.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$119.7M -14.4% | -$104.6M -25.2% | -$83.5M -115.3% | -$38.8M -56.7% | -$24.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $16.0M +7.5% | $14.9M +24.4% | $12.0M +960.0% | $1.1M +5031.8% | $22.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $16.0M +1.3% | $15.8M +32.0% | $11.9M +958.0% | $1.1M +5031.8% | $22.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$103.7M -16.8% | -$88.8M -24.0% | -$71.6M -90.1% | -$37.7M -52.2% | -$24.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 -100.0% | $232.0K | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$103.7M -16.5% | -$89.0M -24.4% | -$71.6M -90.1% | -$37.7M -52.2% | -$24.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +3.2% | -$2 +6.0% | -$2 +66.7% | -$6 -90.2% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +3.2% | -$2 +6.0% | -$2 +66.7% | -$6 -90.2% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $56.7M +20.4% | $47.1M +32.4% | $35.5M +468.8% | $6.2M -20.0% | $7.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $56.7M +20.4% | $47.1M +32.4% | $35.5M +468.8% | $6.2M -20.0% | $7.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.36B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.80B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.71B
Atai Beckley Inc.
NASDAQ:ATAI
$1.47B
Precigen, Inc.
NASDAQ:PGEN
$1.42B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.36B
Immatics N.V.
NASDAQ:IMTX
$1.31B
Nektar Therapeutics
NASDAQ:NKTR
$1.18B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$882.49M
Sana Biotechnology, Inc.
NASDAQ:SANA
$854.36M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ELVN generate?
Enliven Therapeutics, Inc. (ELVN) reported $0.00 of revenue in fiscal 2025.
Is ELVN profitable?
Enliven Therapeutics, Inc. (ELVN) reported -$103,694,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.